New therapy aims to sharpen social skills in schizophrenia
NCT ID NCT00587561
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a group therapy called Social Cognition Interaction Training (SCIT) to help people with schizophrenia better understand social cues. About 51 adults with schizophrenia or schizoaffective disorder took part, either receiving SCIT or being placed on a waitlist. The goal was to see if the training could improve social thinking, symptoms, and everyday functioning.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Social Cognition Interaction Training (SCIT) - a manualized group therapy
- What this could lead to
- If it works, this could offer a new behavioral therapy to help people with schizophrenia better understand social cues and improve daily functioning.
- What could go wrong
- This is a small, early trial with only 51 participants, so results may not apply widely. The therapy is behavioral, not a cure, and benefits may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
51 people
The number who actually took part.
- Start date
-
Jan 2008
- Finished
-
Dec 2023
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * diagnosis of schizophrenia or schizoaffective disorder * Age between 18 and 65 * minimum of 30 days since discharge from last hospitalization * minimum of 30 days since last change in psychiatric medications * no housing changes in the past 30 days Exclusion Criteria: * current diagnosis of alcohol or substance abuse/dependence * history of brain trauma or neurological disease * mental retardation or developmental disability * auditory or visual impairment that would interfere with study procedures
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Connecticut Mental Health Center
New Haven, Connecticut, 06510, United States
-
VA Connecticut Healthcare System
West Haven, Connecticut, 06516, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug